Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 AUG 3 ... protocols using Mycobacterium bovis bacillus Calmette-Guerin (BCG) to prime and modified vacciniavirus Ankara strain (MVA85A) or recombinant attenuated adenoviruses (Ad85A) expressing ... of BCG-vaccinated calves compared to those in BCG-only-vaccinated animals. Analysis of vaccine-induced immunity identified memory responses measured by cultured enzyme-linked ...
2009 OCT 12 ... researchers concluded: "Here, we provide characterization of the ability of a modified vaccinia. virus Ankara vaccine to induce variola. virus-neutralizing antibodies, and we provide ...
2009 AUG 10 ... pulsed with CEA-specific RNA or peptides, or transduced by CEA-expressing adenovirus or vacciniavirus. Because activated DCs do not phagocytose soluble protein antigens efficiently and ... immature DCs are not obtained easily ex vivo, an efficacious whole CEA protein-loaded DC vaccine has not been reported," researchers in Seoul, South Korea report. "To ...
2009 OCT 5 ... "Modified vacciniavirus Ankara (MVA) is an attenuated double-stranded DNA poxvirus currently developed as ... Ankara (MVA) is an attenuated double-stranded DNA poxvirus currently developed as a vaccine vector against HIV/AIDS. Profiling of the innate immune responses induced by MVA is ...
2009 OCT 19 ... T-cell response in LP and IEL compartments after intrarectal immunization with modified vacciniavirus Ankara (MVA). CD8(+) T cells in the IEL compartment had much lower avidity than in ... information, contact I.M. Belyakov, National Cancer Institute, Molecular Immunogenet & Vaccine Research Sect, Vaccine Branch, Center Cancer Research, National Institutes of Health, ...
2009 AUG 4 ... memory T-cell responses in non-human primates following vaccination with modified vacciniavirus Ankara. Rapamycin was effective during both the expansion and contraction phases ... against chronic infections and tumours(1-3). Considerable effort has gone into designing vaccine regimens that will increase the magnitude of the memory response, but there has been ...
2009 AUG 24 ... "While characterizing modified vacciniavirus recombinants (rMVAs) containing human immunodeficiency virus env and gag-pol ... replication system, and a challenge to reduce the occurrence of mutations for vaccine production. Analysis of virus from individual plaques indicated that loss of expression ...
2009 AUG 17 ... gp140, gp140dG, and gp140dV were transferred into plasmid vector and recombinant Tiantan vaccinia (rTTV) vector to generate three DNA vaccines and three rTTV vaccines for vaccination of ... Biotechnology, DNA Research, DNA Vaccines, Gene Therapy, HIV, Human Immunodeficiency Virus, Immunization, Medical Device, Retrovirus, Vaccination, Virology. This ... People's Republic of China, "It remains a great challenge to develop an effective HIV vaccine against the most prevalent HIV-1 clade, B'/C recombinant, in China. Our objective was ...
2009 OCT 5 ... "Here we describe the adaptation of a beta-galactosidase reporter-based vacciniavirus neutralization assay to large-scale use in a study that included over 1,000 ... According to recent research published in the journal Clinical and Vaccine Immunology, "Because of the bioterrorism threat posed by agents such as variola virus, ...
2009 SEP 28 ... in HIV-1-infected long-term non-progressing patients. Both plasmid DNA and modified vacciniavirus Ankara (MVA) vectors supported high expression levels of the HIVB-B*5101 immunogen ... regimen induced efficiently HIV-1-specific CD8(+) T-cell responses in BALB/c mice. These vaccine-elicited T cells were multifunctional, killed efficiently target cells in Vim, and ...
2009 NOV 2 ... the B5 protein, an important neutralizing target of the extracellular envelope form of vacciniavirus (EV)," scientists in the United States report. "LC16m8 elicited a ... "The immune response elicited by LC16m8, a candidate smallpox vaccine that was developed in Japan by cold selection during serial passage of the Lister ...
2009 SEP 7 ... bovis BCG, an attenuated M. tuberculosis mutant strain, a DNA vaccine, a modified vacciniavirus strain Ankara [MVA] construct expressing four TB antigens, and a TB fusion protein ...
2009 SEP 14 ... RSV vaccine-enhanced disease can also be produced in mice by prior vaccination with a vacciniavirus vector containing the RSV G protein, followed by intranasal infectious RSV ...
2009 NOV 2 ... Scientists discuss in 'Lister strain of vacciniavirus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for ... "In this study, we have evaluated the effectiveness of the Lister vaccine strain of vaccinia virus armed with the endostatin-angiostatin fusion gene (VVhEA) as a ...
2009 OCT 5 ... According to a study from the United States, "Attenuated vacciniavirus, modified vaccinia Ankara (MVA) has been engineered to deliver the tumor antigen ... in an open-label phase 2 trial in metastatic renal cell cancer patients in which the vaccine was administered alone or in combination with interferon-alpha-2b (IFN-alpha)." ...
2009 AUG 10 ... against orthopoxviruses. We identified a peptide, EB, which inhibited infection by Vacciniavirus with an EC50 of 15 mc M. A control peptide, EBX, identical in composition to EB ... Biological Therapy, Bioterrorism, Biowarfare, Immunization, Microscopy, Peptide Vaccine, Smallpox, Treatment, Vaccination, Vaccinia Virus, Variola Virus, Viral Inhibition, ...
2009 AUG 17 ... ICAM-1, and LFA-3; TRICOM) as transgenes, including replication competent recombinant vaccinia (rV) or replication-defective modified vaccinia Ankara (MVA), to prime tumor-specific ... "MVA is a potentially safer, replication-defective form of vaccinia virus with unique immunostimulatory properties that could make it a superior priming vaccine. ...
2009 AUG 24 ... vaccination because of their propensity to develop eczema vaccinatum, a disseminated vacciniavirus (VACV) infection," researchers in the United States report. "To ... have renewed efforts to better understand poxvirus pathogenesis and to develop a safer vaccine against smallpox. Individuals with atopic dermatitis are excluded from smallpox ...
2009 SEP 28 ... for patients with squamous cell carcinomas (SCC) of the head and neck. Historically, vacciniavirus was administered widely to humans as a vaccine and led to the eradication of ...
2009 SEP 14 ... aim to develop a mice model to test HIV-1 vaccine efficacy. We constructed a recombinant vaccinia expressing firefly luciferase and HIV-1 Gag fusion protein based on Tiantan strain, an ... Republic of China, "Developing an effective vaccine against human immunodeficiency virus type 1 (HIV-1) remains a grand challenge after more than two decades of intensive ...
